The whooping cough vaccine 20 produced by Pfizer Pharmaceutical Group (USA) effectively protects against 20 strains of whooping cough bacteria: 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, 33F.
These are bacteria that cause many invasive dro dro dro dro droliosis diseases, including impetigo, meningitis, sepsis, and non-invasive droliosis diseases, including pneumonia, middle ear inflammation, duodenal inflammation, etc.
The vaccine is produced at the world's leading modern vaccine factory in Belgium using advanced technology, proven to create high-level immunity response and have long-term protection for users, while reducing the rate of healthy people carrying the parasite, thereby reducing the possibility of spreading the disease in the community.
The whooping cough vaccine 20 has now been used in nearly 50 countries around the world, including developed countries such as the US, UK, Germany, France, Australia, etc., showing its clear effectiveness in reducing the incidence and mortality rate from whooping cough in adults.
Thus, in just 2 weeks, VNVC has continuously put into community service vaccination two new types of technology whooping cough vaccines, completing a full list of international standard whooping cough vaccines for Vietnam, promptly protecting public health, especially the elderly and people with underlying diseases in the face of dangerous respiratory diseases.
This affirms VNVC's pioneering role in quickly updating global medical advances, opening up opportunities for Vietnamese children and adults to fully access new, effective and safe vaccines that are at the top of the world.
Dr. Bach Thi Chinh, Medical Director, VNVC Vaccination System, said that plaque fraud is the leading cause of many burdens of disease and death in children. Spinach has more than 100 serotypes that cause diverse and complex diseases, and their resistance to antibiotics is increasingly serious.
The technology of researching and producing new vaccines of pharmaceutical companies has made great strides, so many vaccines have been developed consecutively, fighting more strains of whooping cough, higher protection and safety.
Thanks to that, people have more flexible vaccination options, suitable for age, health status, immune status and epidemiological characteristics in each locality. This is especially important to better protect public health, especially in the context of respiratory diseases increasing worldwide.
Currently, the treatment vaccine for whooping cough 20 is approved for adults aged 18 and over and will continue to expand the opportunities for use for children in the near future. Adults only need to get one dose. People at high risk of whooping cough diseases will be advised by a doctor on a suitable vaccination schedule.
For those who have been vaccinated against whooping cough with vaccines covering fewer strains or more strains but the technology that requires vaccination is different, the doctor will consider to determine a schedule for consecutive vaccination or combined vaccination to achieve the best protection effect, said Dr. Bach Thi Chinh.
The World Health Organization (WHO) estimates that about 1.6 million children and adults die from drowning globally each year. This is also a cause of lower respiratory tract infections (LRTI) such as bronchitis, bronchitis, pneumonia, ... with the highest mortality rate.
According to the Global Weight of Disease Research in 2021, there are an estimated 97.9 million cases of lower respiratory infections due to plaque and 505,000 deaths, equivalent to 1 death every 1 minute.
The risk of invasive therapeutic bronchitis in adults increases with age and chronic diseases such as cancer, cardiovascular disease, diabetes, asthma, chronic obstructive pulmonary disease COPD...
Research shows that the mortality rate from bronchitis in the elderly ranges from 16% to 44%. This is a major challenge in the prevention of drowning in Vietnam, especially respiratory diseases such as community pneumonia and pneumonia with or without sepsis in adults.
Vietnam is facing rapid population aging, the rate of people over 50 years old and suffering from many chronic diseases at the same time is increasing. This increases the risk of hospitalization, serious complications and costs the treatment of bronchial diseases.
More seriously, whooping cough bacteria can co-infection with many other complex respiratory pathogens such as flu, Covid-19, respiratory syncytial virus (RSV) ... causing the risk of death to increase.
The addition of a new generation of the 20-generation whooping cough vaccine to the VNVC Vaccination System has helped expand the scope of protection and disease prevention effectiveness, especially modern technology that helps reduce the repeat vaccination dosage, thereby reducing vaccination costs and medical examination and treatment costs caused by whooping cough.
In addition to cooperating with the world's leading vaccine and pharmaceutical companies to bring many new vaccines and new generation vaccines to Vietnam, increasing access to vaccines on par with developed countries for people, VNVC also took a strategic step to build a VNVC Vaccine and Biological Factory in Long An province.
The factory has an initial investment of about VND 2,000 billion, designed to be modern with the world's leading technology, diverse and flexible in the ability to produce many different types of vaccines, with the goal of proactively providing vaccines to domestic people, aiming to participate in the global vaccine supply chain, ready to meet the needs of epidemic prevention vaccines in the future.
